TGTX

Tg Therapeutics, Inc.

A biopharmaceutical company focused on B-cell-driven diseases, most notably multiple sclerosis. Its main product, BRIUMVI (ublituximab), is an infusion approved by the US FDA in 2022 to treat relapsing forms of MS. The firm traces roots to 1993 but took the TG Therapeutics name around 2012 under biotech veteran Michael Weiss, and the "TG" initials are commonly tied to its founders.

Recent Activity

Show $

2026Q2

1 buy

Bridgewater Associates LPADD

+118.5K shares(+38.0%)

Bridgewater Associates LPADD

+118.5K shares(+38.0%)

2026Q1

1 sell

Bridgewater Associates LPTRIM

-158.4K shares(-33.7%)

Bridgewater Associates LPTRIM

-158.4K shares(-33.7%)

Loading more activity...